You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

99 search results for: expert insights

The Role of Type 2 Inflammation in Moderate-to-Severe AD
expert video

The Role of Type 2 Inflammation in Moderate-to-Severe AD

Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.
View more
Early Intervention and the Potential For Disease Modification in AD
expert video

Early Intervention and the Potential For Disease Modification in AD

Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson discusses key considerations for disease modification and the importance of early intervention in treating patients with AD.
View more
Emerging Real-World Data on Advanced Systemic Therapies in AD
expert video

Emerging Real-World Data on Advanced Systemic Therapies in AD

Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Marjolein de-Bruin Weller highlights findings from the latest real-world studies on the use of advanced systemic treatments in patients with AD.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Dermatology
Highlights from the ESPD 2023 ADVENT symposium, exploring burden, skin barrier normalization, and current treatments for pediatric atopic dermatitis.
View more
Early Intervention in AD: Latest Clinical and Real-world Data
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Dermatology
Highlights from ESPD 2023 ADVENT: Reviewing the current treatment landscape and the potential for early intervention in pediatric atopic dermatitis.
View more
Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Dermatology
Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.
View more
Most Children With Atopic Dermatitis Have Uncontrolled Disease
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

Dermatology
Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.
View more
UCARE 2023: CSU – The Brazil Perspective
expert video

UCARE 2023: CSU – The Brazil Perspective

Dermatology
Dr. Ensina guides discussions on the perspective of CSU management in Brazil.
View more
When is the right time to consider a biologic in patients with CRSwNP?
expert video

When is the right time to consider a biologic in patients with CRSwNP?

Rhinology
Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.
View more
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Rhinology
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region